

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/125381/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Wheeler, Philip Anthony, Chu, Michael K., Holmes, Rosemary A., Woodley, Owain W., Jones, Ceri S., Maggs, Rhydian, Staffurth, John , Palaniappan, Nachi, Spezi, Emiliano , Lewis, David G., Campbell, Sue, Fitzgibbon, Jim and Millin, Anthony E 2019. Evaluating the application of Pareto navigation guided automated radiotherapy treatment planning to prostate cancer. *Radiotherapy and Oncology* 141 , pp. 220-226. 10.1016/j.radonc.2019.08.001

Publishers page: <http://dx.doi.org/10.1016/j.radonc.2019.08.001>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1     **Evaluating the application of Pareto navigation guided automated radiotherapy treatment planning to prostate cancer**

2     **Philip Anthony Wheeler**<sup>1</sup>; Michael K Chu<sup>1</sup>; Rosemary A Holmes<sup>1</sup>; Owain W Woodley<sup>1</sup>; Ceri S Jones<sup>1</sup>; Rhydian Maggs<sup>1</sup>; John Staffurth<sup>2</sup>; Nachi  
3     Palaniappan<sup>3</sup>; Emiliano Spezi<sup>4</sup>; David G Lewis<sup>1</sup>; Sue Campbell<sup>5</sup>; Jim Fitzgibbon<sup>6</sup>; Anthony E Millin<sup>1</sup>

4     <sup>1</sup>Department of Medical Physics, Velindre Cancer Centre, Cardiff, Wales, United Kingdom

5     <sup>2</sup>School of Medicine, Cardiff University, Cardiff, United Kingdom

6     <sup>3</sup>Department of Oncology, Velindre Cancer Centre, Cardiff, Wales, United Kingdom

7     <sup>4</sup>School of Engineering, Cardiff University, Cardiff, United Kingdom

8     <sup>5</sup>Velindre Cancer Centre, Cardiff, Wales, United Kingdom.

9     <sup>6</sup>Wales Cancer Research Centre, Cardiff University, Cardiff, United Kingdom

10    Corresponding Author:

11    **Phil Wheeler**

12    Department of Medical Physics

13    Velindre Cancer Centre

14    Cardiff

15    CF14 2TL

16    Phone: 02920 615888 ext. 2283

17    [philip.wheeler@wales.nhs.uk](mailto:philip.wheeler@wales.nhs.uk)

18

19